peptide
Adipotide (FTPP)
anecdotalResearch Use OnlyInjection
DISCONTINUED. Experimental peptide that cuts blood supply to fat cells. Terminated due to unacceptable kidney toxicity in primates. No human trials conducted.
Key facts
- Classification
- Peptide — DISCONTINUED: Experimental peptide that cuts blood supply to fat cells. Terminated due to kidney toxicity.
- Primary benefits
- Fat Loss (4/10)
- Administration
- Injection
- Doses studied
- Primate studies only (Barnhart et al. 2011, PMID 22072637, DOI 10.1126/scitranslmed.3002621, Science Translational Medicine 3(108):108ra112). In an initial dose-finding study in 4 obese female rhesus macaques, the subcutaneous daily dose was raised through 0.10, 0.25, 0.43, and 0.75 mg/kg, stepping up every 2 weeks, for 63 consecutive days. On efficacy and toxicity, 0.43 mg/kg daily subcutaneous was chosen as the optimal therapeutic dose. It was then given for 28 consecutive days, followed by a 4-week recovery. A GLP toxicology study in lean rhesus monkeys gave 0.25, 0.43, or 0.75 mg/kg daily for 28 days. Kidney effects were dose-dependent. Serum creatinine rose at doses above 0.25 mg/kg. Twenty-four hours after the final 0.75 mg/kg dose there was mild tubular degeneration, moderate regeneration, and single-cell necrosis. Most serum and urine changes reversed within 28 days of stopping, but minimal tubular degeneration was still present after recovery in 1 middle-dose and 2 high-dose monkeys. Phase 1 human trial (NCT01262664; lead sponsor M.D. Anderson Cancer Center): subcutaneous injection once daily for 28 days, at a registered starting dose of 0.03 mg/kg. It was terminated at the PI's request (completion 2019-01-02), and no results were posted. The 0.01 mg/kg research-protocol dose and 2-week cycle limit cited in secondary sources have no PubMed-indexed primary basis. No human clinical dose established. Monitor renal function. Use at your own risk.
- Evidence strength
- Anecdotal — 8 peer-reviewed studies
- Legal status
- Research Use Only · not prescribable in US
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 8
- Stacks with
- 0 peptides
- Regulatory
- Research Use Only
Goal coverage · Adipotide (FTPP)
🔥 Fat Loss4/10
Medical oversight requiredNot safe during pregnancy· 5 contraindications